An in vitro study conducted by Majumder et al. [150] created a multicomponent and multifunctional cancer-targeted delivery system, containing Nanostructured Lipid Carriers (NLCs) as vehicles, luteinizing hormone-releasing hormone (LHRH) as a cancer-targeting moiety, siRNA targeted to EGFR mRNA as a suppressor of EGF receptors, EFG-TK inhibitor gefitinib and/or paclitaxel as anticancer drugs, and an imaging agent (Rhodamine) for the visualization of cancer cells. Here, EGFR is linked to cancer.